RxDoctor Payments Data

Christina Howell, APRN

Psychiatric/Mental Health · Louisville, KYNPI 1316659345

Payments from drug & device makers

$1,207in general payments, 2019–2025

Across 36 payments — averaging $33.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$550
  • AbbVie$188
  • Teva Pharmaceuticals USA, Inc.$111
  • Lundbeck LLC$92
  • Otsuka America Pharmaceutical, Inc.$87
  • Corium, LLC$78
  • plus $101 from 5 others

What the payments were for

  • Food & beverage$1,09691%
  • Education$1119%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,207 in reported general payments places this provider in the 60th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$13,660
Medicare patients
27
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate184$628,813
IngrezzaValbenazine Tosylate56$245,060
Abilify MaintenaAripiprazole68$201,443
AristadaAripiprazole Lauroxil37$119,019
Austedo XrDeutetrabenazine21$86,562
UzedyRisperidone18$52,446
AustedoDeutetrabenazine14$32,688
Clozapine177$11,036
Divalproex Sodium235$9,167
Divalproex Sodium ErDivalproex Sodium190$4,415
Haloperidol Decanoate70$3,649
Olanzapine190$2,843
Memantine Hcl78$2,070
Propranolol Hcl210$1,932
Benztropine Mesylate246$1,924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$39$628,813184 claims
Neurocrine Biosciences, Inc.Ingrezza$14$245,06056 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$87$201,44368 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy, Austedo$111$171,69553 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →